Kazia Therapeutics (NASDAQ: KZIA) director Coffey details ADS options and share stakes
Rhea-AI Filing Summary
Kazia Therapeutics director Steven R. S. Coffey filed an initial ownership report showing his equity interests in the company. He holds options over 1,000 American Depositary Shares (ADSs) at an exercise price of $0.3348 expiring on April 30, 2027, granted on April 30, 2024 with quarterly vesting over three years, and options over 75,000 ADSs at $8.00 expiring on July 3, 2027, which vested fully on July 3, 2025. He also directly owns 16,000 ordinary shares. Additional ADS holdings of 845 and 1,122 are held by Coffey Family Investments Pty Limited and Fortune 501 Pty Limited, respectively, and Coffey disclaims beneficial ownership of those securities except for any pecuniary interest. Each ADS may be exchanged at any time for 500 ordinary shares, and the ADSs themselves have no expiration date.
Positive
- None.
Negative
- None.
Insider Trade Summary
5 transactions reported
Mixed
5 txns
Insider
Coffey Steven R. S.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | American Depositary Share Option (Right to Buy) | -- | -- | -- |
| holding | American Depositary Share Option (Right to Buy) | -- | -- | -- |
| holding | American Depositary Shares | -- | -- | -- |
| holding | American Depositary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
American Depositary Share Option (Right to Buy) — 76,000 shares (Direct);
American Depositary Shares — 1,967 shares (Indirect, See footnote);
Ordinary Shares — 16,000 shares (Direct)
Footnotes (6)
- F1. The American Depositary Shares ("ADSs") subject to the option ("ADS option") vest in equal quarterly installments over three years beginning on April 30, 2024, subject to the Reporting Person's continuous service relationship with the Issuer through each applicable vesting date. The ADS option was granted on April 30, 2024.
- F2. Each ADS option is convertible into ADSs upon exercise.
- F3. Each ADS may be represented by 500 ordinary shares of the Issuer, no par per share (the "Ordinary Shares"), at any time, upon the holder's election to surrender the ADSs and withdraw the respective number of Ordinary Shares. The ADSs have no expiration date.
- F4. The ADSs subject to the ADS option vested as to 100% on July 3, 2025. The ADS option was granted on July 3, 2025.
- F5. The ADSs are held directly by Coffey Family Investments Pty Limited, of which the Reporting Person is a director. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 3 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
- F6. The ADSs are held directly by Fortune 501 Pty Limited. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 3 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does Steven Coffey report owning in Kazia Therapeutics (KZIA) on this Form 3?
Steven Coffey reports options over 1,000 ADSs at $0.3348, options over 75,000 ADSs at $8.00, and 16,000 ordinary shares. He also reports indirect interests in 845 and 1,122 ADSs held by two separate entities.
How do the Kazia Therapeutics (KZIA) ADS options held by Steven Coffey vest and expire?
One ADS option over 1,000 ADSs was granted on April 30, 2024 and vests in equal quarterly installments over three years, expiring on April 30, 2027. A second ADS option over 75,000 ADSs vested 100% on July 3, 2025 and expires on July 3, 2027.
Which entities hold indirect Kazia Therapeutics (KZIA) ADS positions associated with Steven Coffey?
Indirect ADS holdings are reported for Coffey Family Investments Pty Limited and Fortune 501 Pty Limited. They hold 845 and 1,122 ADSs respectively. Coffey is a director of Coffey Family Investments Pty Limited and disclaims beneficial ownership in both entities except for any pecuniary interest.
Does this Kazia Therapeutics (KZIA) Form 3 show any recent buying or selling by Steven Coffey?
No specific buy or sell transactions are identified; the entries are reported as holdings. The filing summarizes Coffey’s existing options, direct ordinary share ownership, and indirect ADS interests, rather than recording new market purchases or sales.